1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

A Competitive Analysis of the Global Asthma and COPD Therapeutics Market : Novel Inhaler Devices and Formulations are Impetuses for Growth

  • October 2014
  • 69 pages
  • Frost & Sullivan
Report ID: 2464464


Table of Contents

Key Findings

•Chronic obstructive pulmonary disorder (COPD) is the third leading cause of death in the United States, and is in fourth place in Europe and the rest of the world.
•An estimated xxmillion people are affected by COPD globally. By 2020, COPD is projected to be the third leading cause of death globally.
•Limited communication between medical practitioners and patients limits early diagnosis of the disease.
•It is estimated that only xx% of smokers detect the onset of COPD symptoms and seek medical advice and treatment.
•Bronchodilators, anti-inflammatories, and combination therapies are prime segments used in evaluating asthma and COPD therapeutics.
•Combination therapies such as Symbicort Turbuhaler, Relvar Ellipta, and Anoro Ellipta show promising market acceptance due to increased clinical benefits of higher drug efficacy, especially in patients with increased disease severity.
•Bronchodilators are widely used to manage mild to moderate symptoms associated with COPD.
•Patent expiration of blockbuster drugs such as Advair (known as Seretide in the European Union) widen pipeline investment opportunities to meet therapeutic demand.


•Teva Pharmaceuticals, AstraZeneca, Novartis, Merck & Co., and Boehringer Ingelheim are among the Tier I participants in this market.
•Upcoming drugs include:
oDuoResp Spiromax, an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist combination therapy drug by Teva Pharmaceuticals (approved, pending launch).
oStriverdi Respimat (olodaterol), a bronchodilator by Boehringer Ingelheim (approved, pending launch).
oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic attacks.
oNovartis’ QMF149 Twisthaler is under drug safety trial to assess its effect on asthma exacerbations, and is expected to arrive in the market by 2017.


•Striverdi Respimat is approved in the United Kingdom, Denmark, and Iceland based on results obtained from Phase 3 trials, which displayed remarkable improvements in lung functions with the use of the drug as an addition to the usual care drugs in COPD patients. The estimated launch in the United States and Japan is expected to be either in the last quarter of 2014 or the first quarter of 2015.
•GSK and Theravance’s jointly developed drug, GSK961081, is classified as a bifunctional molecule developed with muscarinic antagonist and ?2-agonist (MABA) properties to be used by COPD patients. It is in Phase 2 in Australia.

CEO’s Perspective

Development of innovative COPD therapeutics to check inflammations and exacerbations in patients will increase.
The patent expiry of blockbuster drugs such as Advair opens investment opportunities for strengthening pipeline portfolios to meet the rising drug demands.
Interest in developing combination therapies is growing because of their higher therapeutic efficacy.
The high economic burden due to the rise of COPD incidence creates tremendous investment opportunities.
Limited knowledge of the disease, limited drug classes, and an absence of a permanent cure increases investment interest in the market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Targeted Therapies in Asthma - 2017

Targeted Therapies in Asthma - 2017

  • $ 8355
  • Industry report
  • February 2017
  • by Firstword Pharma

Description As new targeted asthma therapies emerge, is time running out for Xolair? Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala ...

Asthma Treatment Drugs Markets in China

Asthma Treatment Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

Acute Asthma Global Clinical Trials Review, H1, 2017

Acute Asthma Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • February 2017
  • by GlobalData

Acute Asthma Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Acute Asthma Global Clinical Trials Review, H1, 2017" provides an overview of Acute Asthma clinical ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.